INVIEW secures Pre-A round funding to accelerate development of innovative high-end optical imaging platform for biomedicine

Recently, INVIEW announced the completion of its Pre-A round of financing. This round was exclusively invested by the Shanghai Industrial Intellectual Property Fund ("Xinju Ceyuan Phase I Fund") under Shanghai STVC Group. The funds raised will be used to build an innovative platform for high-end optical imaging in biomedicine, accelerating the R&D iteration, production capacity enhancement, and expansion of Chinese and international market channels for INVIEW's multiple independently developed high-end optical microscopic imaging instruments and biomedical solutions.

INVIEW is a national high-tech enterprise specializing in high-end microscopic imaging systems and integrated solutions for biomedicine. The company's core technical team brings together research expertise from top institutions such as The Hong Kong University of Science and Technology, Fudan University, and the Chinese Academy of Sciences. They have successfully established an interdisciplinary scientific innovation and technology transformation platform that integrates optics, biology, automatic control, mechanical engineering, information technology, and artificial intelligence. INVIEW not only possesses the capability for original innovation and disruptive technology development from 0 to 1 but also excels in integrated innovation and efficient industrialization from 1 to N.

The core product of INVIEW is the iSTORM ultra-high-resolution microscopic imaging system, which successfully commercializes the achievements of the 2014 Nobel Prize in Chemistry—ultra-high-resolution microscopy technology. This system boasts an internationally leading ultra-high resolution of 20 nanometers, enabling ultra-high-resolution imaging at the level of live cells and single molecules. It serves as a "powerful scientific tool" for analyzing cellular molecular composition, localizing and counting biomacromolecules, resolving subcellular structures, and tracking molecular dynamic processes. With broad application prospects in biomedical frontier exploration, drug and vaccine development, and quality control of nano-delivery systems, it empowers researchers to observe the microscopic world from an unprecedented perspective.

Building upon its deep expertise in high-end imaging, INVIEW further empowers critical scenarios in life science research with cutting-edge optical and imaging technologies. From super-resolution imaging that reveals molecular mysteries, to long-term culture imaging for real-time monitoring of cell growth, and intelligent counting imaging that provides precise data for cell studies, INVIEW has developed the Cellaview live-cell imaging series and the INCount cell counter series alongside its iSTORM product line. This integration of advanced technologies into the entire research and industrial chain meets core demands for cellular data across fields ranging from basic scientific research to cell therapy and drug development.

Beyond the iSTORM series, INVIEW has also introduced:

Cellaview Live-Cell Imaging Series: This product line deeply integrates AI recognition technology, enabling real-time, non-invasive, high-definition imaging and monitoring of cells inside CO₂ incubators. It effectively addresses the limitations of traditional manual observation, such as cumbersome operations, contamination risks, and the inability to conduct continuous tracking. Widely used in applications including wound healing (scratch) assays, confluency analysis, organoid culture monitoring, tumor spheroid proliferation monitoring, and stem cell growth monitoring, it provides an intelligent, one-stop solution for cell quality control.

INCount Intelligent Cell Counter Series: Empowered by AI for next-generation cell counting, this series combines proprietary high-definition imaging technology with deep learning algorithms to accurately identify cell morphology and intelligently analyze cell clusters, completely eliminating the tedious processes and subjective errors associated with traditional manual counting. The product line includes various models, such as fully automated and consumable-free options, improving cell counting efficiency by a hundredfold. It has gained high recognition from numerous research institutes, medical institutions, and biopharmaceutical companies.